We previously demonstrated expression of the HST-1/ FGF-4 gene in the testis of normal adult animals, which suggests its possible role in spermatogenesis. For an understanding of its functional signi®cance in the testis, conditional transgene expression was used. Precise genetic switches can be eciently generated in a straightforward manner using adenovirus-carrying Cre recombinase, which means our new strategies promise to contribute substantially to a better and prompt understanding of the functions of genes in vivo by controlling the expression of any gene to any organ at any desired time. Our new method demonstrated for the ®rst time that the speci®c gain of function of the HST-1/FGF-4 gene in the testis resulted in markedly enhanced spermatogenesis. To further investigate the function and therapeutic potency of HST-1/FGF-4, transgenic mice with enhanced HST-1/FGF-4 expression in the testis were exposed to adriamycin (ADR), an anticancer drug causing severe testicular toxicity. Degree of damage to spermatogenesis was assessed by sperm count, testicular weight, histology, and DNA ploidy. Induced expression of HST-1/FGF-4 markedly enhanced the recovery of ADR-induced testicular damage. Furthermore, adenoviruses carrying the HST-1/FGF-4 gene ameliorated testicular toxicity of ADR. These results with new adenovirus-mediated Cre/lox conditional mice indicated that HST-1/FGF-4 could be an important factor for spermatogenesis, presenting a new paradigm to treat impaired fertility.
Introduction
The HST-1 gene was ®rst cloned in our laboratory as a transforming gene in the NIH3T3 assay system and identi®ed as a gene belonging to the ®broblast growth factor (FGF) gene family, FGF-4 (Sakamoto et al., 1986; Yoshida et al., 1991) . The product, HST-1/FGF-4 is especially involved in embryogenesis (Suzuki et al., 1992; Martin, 1992, 1993; Niswander et al., 1994; Ochiya et al., 1995) . Up-regulation of HST-1/ FGF-4 gene expression is associated with human testicular tumors (Yoshida et al., 1988) . As to its biological activities, we have previously shown that it is a factor with a potent angiogenic activity (Yoshida et al., 1994) as well as a potent inducer of platelet production from megakaryocytes Konishi et al., 1995 Konishi et al., , 1996 . Most of the other FGF family genes have their expression not only in the embryonic stage but also in several adult tissues. However, it was noted that the HST-1/FGF-4 gene is normally dormant in adult tissues, and the physiological functions of its production of adult bodies were still unknown. We have designed highly sensitive RT ± PCR analyses and found that adult murine and human HST-1/FGF-4 gene expression were detected predominantly in the testis, nervous system, and intestines, being weakly recognized in other tissues. By in situ hybridization, we also showed cell type-speci®c HST-1/ FGF-4 gene expression in Sertoli cells in the testis and in Purkinje cells in the cerebellum (Yamamoto et al., 2000) . These results suggest that the HST-1/FGF-4 gene may also play some speci®c roles in adult tissues as well as in embryos.
The presence of HST-1/FGF-4 gene expression in Sertoli cells within the testis was of great interest with regard to spermatogenesis, since the whole process of dierentiation of male germ cells depends on a complex network of endocrine and paracrine communication involving a variety of supporting cells (Sharpe, 1994) . In the seminiferous tubule, spermatogenic cells are in continuous contact with Sertoli cells, which indicates that Sertoli cells play a critical role in germinal-cell dierentiation . A number of endocrine agents and locally produced paracrine factors were shown to control and maintain Sertoli cell function and dierentiation (Griswold, 1988) . Among them, FGF-2 was found to signi®cantly increase the number of Sertoli cells and also stimulate the proliferative activity of the gonocytes in vitro (Van Dissel-Emiliani et al., 1996) . FGFR-1 and FGFR-4 are known to be localized in Sertoli cells in rat testis (Van Dissel-Emiliani et al., 1996; Cancilla and Risbridger, 1998; Le Magueresse-Battistoni et al., 1994) and normal human germ cells (Steger et al., 1998) . All these reports suggest possible signi®cance of FGF gene family and their receptors in spermatogenesis.
The studies we present here were designed to show that the HST-1/FGF-4 gene promotes spermatogenesis in vivo and that it may participate in the regulation of spermatogenesis. For this purpose, as an ecient and accurate method for controlled in vivo transgene modulation by site-directed Cre recombinase, we established a transgenic animal carrying the dormant HST-1/FGF-4 gene. This is a powerful tool for both designing such genetic switches and speeding the creation of gene-activated animals by the use of Cre site-speci®c DNA recombinase (Sauer, 1998) . Precise genetic switches can be eciently generated in a straightforward manner using an adenovirus that carries Cre recombinase (Kanegae et al., 1995) . Our recombination-based conditional gene activation strategies in vivo can be used to design induced expression of any gene to any tissue at any desired time, and will have a profound impact on fundamental biology and the design of better therapeutic models of human diseases.
By administration of Cre-expressing adenoviruses in vivo, we accomplished conditional high expression of the HST-1/FGF-4 transgene and, more importantly, found that high expression in these mice resulted in an increased sperm count and resistance to age-dependent and ADR-induced impaired spermatogenesis. Moreover, ADR-induced testicular toxicity was ameliorated by injection of adenoviruses carrying the HST-1/FGF-4 gene into testis. Thus, these data suggest that HST-1/ FGF-4 is an important factor in spermatogenesis and indicate the possibility that this gene may present a new approach for male infertility.
Results
Inducible HST-1/FGF-4 gene activation in mice using the Cre/lox system To assess the functional role of HST-1/FGF-4 gene products in the testes for spermatogenesis in vivo, Cre recombinase-regulated conditional transgenic mice were generated (Figure 1a ). In this system, the recombinase is provided by the adenovirus-carrying Cre gene (AxCANCre) (Kanegae et al., 1995) . When a sucient amount of Cre is supplied, the stuer sequence is excised as circular DNA, and then the CAG promoter and the HST-1/FGF-4 gene are joined via a single loxP site, thereby initiating target gene expression in the target tissue. Eight independent transgenic-mouse founder lines harboring the switching unit were obtained. No abnormalities among founders and/or their progenies were observed. To see whether conditional gene expression was attained in transgenic mice, 1.0610 8 p.f.u of AxCANCre per testis was administered. As a control, the other testis of the pair + RNA was extracted and subjected to RT ± PCR analysis to detect HST-1/FGF-4 gene activation. The same RNA samples were subjected to RT ± PCR analysis of bactin transcripts to verify their integrity (Figure 1b) . It was also shown that mRNAs from other tissues such as brain, lung, liver, and kidney revealed no mRNA products. Testes-speci®c Cremediated gene activation was con®rmed in three independent transgenic-mouse founders. Our previous reports suggest that the Cre-mediated switching of gene activation was determined nearly 100% in cultured cells (Kanegae et al., 1995) . To determine the frequency of gene activation and cell type in testes, in situ hybridization analyses were performed. The results showed that human HST-1/FGF-4 mRNA was primarily detected in spermatocytes, and Sertoli cells and some spermatogonia in Cre injected mice (Figure 2a ), while the expression of the transgene cannot be demonstrated in mice that were not injected with Cre ( Figure 2b ). In addition, RT ± PCR analysis showed that human HST-1/ FGF-4 gene activation had actually occurred in puri®ed Sertoli cells from Cre-injected testes (Figure 1c ). These results con®rm that HST-1/FGF-4 transgene activation had occurred only in the testes, as predicted, via precise site-directed deletion of the stuer sequences in the conditional transgenic mice carrying the dormant transgene.
Enhanced spermatogenesis in mice from HST-1/FGF-4 expression
To study the eects of HST-1/FGF-4 in spermatogenesis, three independent transgenic mice lines were administered 1.0610 8 p.f.u. of AxCANCre per testis, and then testis weights and sperm counts were examined. An increase in sperm count was ®rst observed at 2 weeks after the administration in all mice lines with AxCANCre as compared to the control animals. The most evident increase in the sperm count was observed 4 weeks after the administration (Figure 3 ): 17.2+2.2610 6 /ml of AxCANCre and 12.9+0.5610 6 /ml of AxCAwt (P50.001). No gross abnormalities in sperm parameters including morphology and motility were observed. Increased testis size was seen 4 weeks after the AxCANCre administration. Testes from mice administered AxCANCre exhibited a 15% increase in testes weight as compared to the control animals. A cross-section of the seminiferous tubules of these testes was comparable with that of the control mice; the number of spermatogonia had increased, while that of Sertoli cells had not (data not shown). The diameter of the seminiferous tubules was not signi®cantly changed. BrdU incorporation analysis showed that AxCANCre-administered testes contained an increased number of BrdU-positive spermatogonia relative to the control group (Figure 4 ). The labeling indices were 28.9+3.7% in mice with AxCANCre and 5.7+1.1% in mice with control AxCAwt (P50.001). These results suggest that forced HST-1/FGF-4 gene 
HST-1/FGF-4 blocks age-dependent sperm decrease
The eect of HST-1/FGF-4 on age-dependent change of sperm count was analysed. Increased sperm count continued to be observed at least 45 weeks after the AxCANCre administration and these mice with a high number of sperm were normally fertile. The sperm count of control animals that received AxCAwt decreased in an age-dependent manner, and at 75 weeks after the adenovirus treatment, the sperm count shows 2.4+0.3610 6 /caudal epididymis. In contrast, at the same age, mice with AxCANCre showed a sperm count of 11.2+2.4610 6 /caudal epididymis (P50.001), which is equivalent to that of control young adult at 10-weeksold ( Figure 5 ). Histological analysis showed that the number of spermatogonia and spermatocytes was not diminished when testes were injected with AxCANCre ( Figure 6b ). However, testes from control mice administered with AxCAwt showed a diminished number of both types of cells, indicating age-dependent changes ( Figure 6a ). Furthermore, mice with AxCANCre revealed normal fertility at 86-weeks-old (n=4, 100% fertile) whereas control mice were infertile (n=4, 0% fertile). The results obtained indicated that HST-1/FGF-4 worked as a protective agent against age-dependent changes in male fertility.
Effects of HST-1/FGF-4 on drug-induced testicular toxicity
Experiments were performed to investigate the eects of HST-1/FGF-4 on drug-induced toxicity against testis. One week prior to the administration of ADR to induce testicular toxicity, one group of male transgenic mice was injected with 1.0610 8 p.f.u. of AxCANCre into testis. As a control, an adenovirus vector without HST-1/FGF-4 gene was administered into testis. These mice received one intraperitoneal injection of ADR every week for 3 weeks at a dose of 2.0 mg/kg. Thereafter, they were periodically sacri®ced for the examination of number, motility and the morphology of the sperm together with weight of the testis. ADR treatment caused a decrease in body weight, testis weight, sperm counts and sperm motility and an increase in the percentage of morphologically abnormal sperm in the control mice. The sperm counts of the control mice reached to the lowest levels in week 7 after the ADR treatment of 2.0+1.1610 6 /caudal epididymis, corresponding to an 86% decrease ( Figure  7a ). In contrast, the AxCANCre-injected group showed the lowest levels in week 5 of 6.6+1.2610 6 /caudal epididymis (P50.003), corresponding to only a 59% decrease, with their sperm counts returning to the pretreatment level by week 13. Changes in testis weight showed that AxCANCre-injected mice revealed enhanced recovery from ADR damage while the testis weight of the control mice signi®cantly decreased 7 weeks after the ADR treatment and remained reduced for an additional 8 weeks (Figure 7b ). Sperm motility was signi®cantly decreased in the control mice 4 weeks after the ADR treatment (12+2%), while the AxCANCre-administered mice showed 42+5% sperm motility (P50.01) and then rapidly recovered to a normal level by week 10 (64+7%). Although the data are not shown here, a comparison of the DNA histogram by¯ow cytometry revealed that AxCANCre-administered mice showed signi®cant recovery of haploid cells (spermatid, 1C) at week 13, in agreement with the recovered point of sperm count. Furthermore, testicular histology revealed that the number of spermatogonia and spermatocytes recovered in the AxCANCre-injected mice 10 weeks after the ADR treatment (Figure 8c ). However, testes from control mice administered with AxCAwt showed a diminished number of both types of cells 10 weeks after the ADR treatment, indicating that severe testicular toxicity was present (Figure 8b ) as compared to normal testis (Figure 8a ). The results obtained indicated that HST-1/FGF-4 worked as a protective agent against ADR-induced testicular toxicity.
Effects of HST-1/FGF-4 on fertility in ADR-treated mice
We assessed the eect of HST-1/FGF-4 on ADRtreated male fertility 10 weeks after the ADR treatment. Transgenic male and normal female mice were housed together overnight on a 1 : 1 basis in the home cage of the male. No pregnant animals were obtained in the control mice with ADR-treated alone. In contrast, successful pregnancies were observed in three of ®ve male mice with AxCANCre. The mean litter size was six to seven. Consequently, these results indicate that HST-1/FGF-4 contributes to the recovery of ADR-induced male infertility.
Adenovirus-mediated HST-1/FGF-4 gene transfer effectively recovered sperm count in ADR-treated mice
To explore the therapeutic usefulness of the HST-1/ FGF-4 gene on impaired spermatogenesis, 1.0610 8 p.f.u. of adenovirus carrying the HST-1/ FGF-4 gene (AxHST-1) per testis was administered into testis of mice 4 weeks after the 2 mg/kg ADR treatment. As a control, adenovirus without HST-1/ FGF-4 gene (AxCAwt) was injected. The sperm count of the AxHST-1-injected group showed a dramatic recovery 10 days after the adenovirus injection (P50.05), while the sperm count of the control groups administered with AxCAwt severely decreased ( Figure  9 ). In the AxHST-1-treated mice, a signi®cant decrease in the diameter of the seminiferous tubules was also observed (data not shown). These results suggest that the gene transfer of HST-1/FGF-4 has a protective eect on experimentally induced testicular toxicity in mice.
Discussion
A method for activation or inactivation of a transgene in animals has recently been accomplished by using site-speci®c recombinases Cre and FLP (Werdien et al., 2001) . However, this current system of transfer recombinase in vivo using either gene transfer or crossing Cre-expressing animals was low in eciency and time-consuming. Here we report for the ®rst time that a simple inoculation of Cre-expressing adenovirus into a target organ allows genetic switching-on in transgenic animals. Our adenovirus-mediated recombinase-based conditional gene activation strategies in vivo can be used to design induced expression of any gene to any tissue at any desired time, and will have a profound impact on fundamental biology and the design of better therapeutic models of human diseases. By establishing Cre/lox conditional transgenic animals in which testis-speci®c gain of function of the HST-1/ FGF-4 gene resulted in enhanced spermatogenesis, we have demonstrated that this gene has a protective eect against testicular toxicity induced by an anticancer drug. In those animals, impaired fertilization ability also recovered. In addition, we have successfully shown the therapeutic eectiveness of the adenovirus carrying HST-1/FGF-4 gene against oligozoospermia in mice. To our knowledge, this is the ®rst demonstration of gene therapy against drug-induced male infertility in animal models.
The present results that the HST-1/FGF-4 gene can correct anticancer drug-induced male infertility provides us with the possibility of treatment of human drug-or radiation-induced oligozoospermia. There are controversial disputes over decreases in sperm counts in young, seemingly healthy people worldwide, and some people attribute the decrease to the presence of endocrine disrupters. Whether there is in fact a decrease in sperm counts worldwide is yet to be determined, but male infertility accompanied by decreased sperm counts is a serious problem for some people (Ford, 2001 ). Therapeutic approaches for male infertility have been developed including spermatogonial stem cell transplantation (Avarbock et al., 1996; Ogawa et al., 2000) . These methods, however, are highly invasive and expensive treatments. Our results suggest that HST-1/FGF-4 gene therapy can be used to treat some people with oligozoospermia unrelated to drug toxicity, indicating hope of development of better treatments for male infertility.
The mechanism by which HST-1/FGF-4 stimulates spermatogenesis in vivo has not been established. FGF-2 produced from Sertoli cells was found to signi®cantly increase the number of Sertoli cells and also stimulate the proliferative activity of the gonocytes in vitro (Van DisselEmiliani et al., 1996) . The presence of continuous expression of the Hst-1/Fgf-4 gene in Sertoli cells was a novel ®nding, and this observation has led us to speculate that HST-1/FGF-4 could be involved in speci®c signals during sperm maturation. For example, Hst-1/Fgf-4 gene expression in testis was found during the period that the animals retained their fertility (Yamamoto et al., 2000) and the expression was decreased thereafter. In addition, inhibition of HST-1/FGF-4 gene expression by antisense ODNs against this gene decreased the sperm count in vivo (unpublished observations). Furthermore, the signi®-cance of HST-1/FGF-4 is supported by the reports that FGFR-1 and FGFR-4 are known to be localized in Sertoli cells in rat testis and that FGFR-1, -2, -3 and -4 are present in adult germ cells (Cancilla and Risbridger, 1998; Le Magueresse-Battistoni et al., 1994) . We have con®rmed that FGFR-1 and FGFR-2, which are known as highanity receptors for HST-1/FGF-4, are expressed in murine spermatogonia (data not shown). Considering that overexpression of HST-1/FGF-4 does not lead to apparent growth of Sertoli cells in testis, enhanced spermatogenesis in our system may result from HST-1/ FGF-4 acting as a paracrine growth and/or dierentiating factor on spermatogonia.
ADR, an anticancer drug well known for its testicular toxicity, was used in this study. It is known that ADR inhibits RNA and DNA synthesis through interaction into the double-helix, thereby interfering with cell division Simpkins and Pearlman, 1984) and induces chromosomal aberrations (Russo and Levis, 1992) . ADR tended to kill type A spermatogonia at all stages of the spermatogenic cycle (Matsui et al., 1993) and induces apoptotic death (Sjoblom et al., 1998; Shinoda et al., 1999) . There is a possibility that HST-1/FGF-4 protects against ADRinduced apoptotic death of spermatogonia. FGFs has been shown to protect tissue damage in animal models of drug-induced apoptosis (Wagle and Singh, 2000) and in vitro cultured cells (Miho et al., 1999; Haimovitz-Friedman et al., 1994) . The cellular and molecular mechanisms of FGFs eects have not been fully de®ned; thus, further investigation of the protective eect of HST-1/FGF-4 on ADR-mediated germ cell death is required.
Male germ cell tumors often overexpressed the HST-1/FGF-4 gene (Strohmeyer et al., 1991) . Therefore, there is potential for HST-1/FGF-4 to stimulate tumor growth in vivo when this gene is used in a clinical setting for human gene therapy. Although our conditional transgenic mice with continuous HST-1/ FGF-4 gene expression in testes produced no tumor growth through more than a period of 1 year and 10 months (unpublished observations), further careful analyses are required before our adenovirus-carrying HST-1/FGF-4 gene can become an ideal gene therapy for male infertility. Adventitious germ-line integration of transferred gene in the course of somatic gene therapy is an ethical concern that must be addressed. In our study, adenovirus injection was performed by intratesticular injections, thereby germ cells and sperm were directly exposed to a high titer of adenovirus. However, in our experiments, we have not observed germ-line integration of the transferred genes. In addition, it has been reported that mouse germ-line integration event is minimal in adenovirus injection into testes (Hall et al., 2000) . However, further careful studies are required to see whether germ-line integration of exogenous gene is not occurred to the damaged testes before our method is applied for human gene therapy.
Finally, our results have important implications for clinical applications of the HST-1/FGF-4 gene for oligozoospermia and male infertility, in addition to furthering an understanding of the mechanisms involved in the eects of this gene on spermatogenesis.
Materials and methods

Recombinant DNA constructs and conditional transgenic mice
The CALNLHST-1 switching unit was constructed according to the original method (Kanegae et al., 1995) . In brief, 1901 bp of a full-length of human HST-1/FGF-4 cDNA fragment was cloned into the SwaI site of plasmid pCALNLw consisting of the CAG promoter, a loxP sequence, a neo-resistant gene (1.0 kb of the BglII ± SmaI fragment from pSV2neo), a second loxP site, and the poly(A) signal from pCAGGS, resulting in a transgene named CALNLHST-1. The transgene was linearized and injected into C57BL/6J mouse (CLEA Japan Inc., Japan) zygotes at a concentration of 2 mg/ml to generate transgenic mice according to an established procedure (Hogan et al., 1986) . Transgenic founder mice were mated to C57BL/6J mice, and ospring were screened for the presence of the transgene by Southern blot analysis of genomic DNA isolated from tail biopsies at the age of 3 weeks.
Switching of the transgene by AxCANCre
A recombinant adenovirus expressing Cre recombinase (AxCANCre) was prepared as described (Kanegae et al., 1995) . As a control, an empty adenovirus vector was used (AxCAwt). The virus stock was concentrated and puri®ed at 9 p.f.u./ml as described previously (Kanegae et al., 1994) . Transgenic mice were administered 1.0610 8 p.f.u. of AxCANCre or control AxCAwt per testis. Mice were sacri®ced at various times, and testis weights, caudal epididymal sperm counts and sperm motility were investigated.
Testes specific HST-1/FGF-4 gene activation by Northern blot hybridization
In order to evaluate the testes speci®c gene expression in Creswitching mice, Northern blot hybridization analysis was performed. One day after the intratesticular administration of AxCANCre into right testis, total RNA was harvested from testes and other organs. Left testis was remained untreated as a control. Ten mg of each total RNA sample was separated on a denatured 1% agarose gel, transferred to a NitroPlus nitrocellulose membrane (Micron Separations Inc., MA, USA), and the blot was hybridized with the a 32 P-dCTPlabeled full-length of human HST-1/FGF-4 cDNA as a probe in the presence of 50% formamide for about 18 h. As an internal reference, the same ®lter was later hybridized to a bactin probe. The images were incorporated into Macintosh computer through a STORM image scanner (Molecular Dynamics). Intensity of each band on the image was measured and the data were processed by an image processing software ImageQuant.
Localization of HST-1/FGF-4 gene expression by in situ hybridization
Digoxygenin-labeled sense or antisense riboprobes were synthesized by T3 or T7 RNA polymerase from cDNA plasmids containing the entire coding sequences of human HST-1/FGF-4 cDNA in the presence of digoxygenin-dUTP (Roche Diagnostics, GmbH, Germany). In situ hybridization experiments using fresh-frozen testis sections and digoxygenin-labeled riboprobes were carried out essentially as described previously (Ishii et al., 1997; Wilkinson, 1992) .
Cell isolation
Sertoli cells were isolated from AxCANCre injected testes. In brief, testes were decapsulated in ice-cold Minimum essential medium (MEM, Life Technologies Inc., MD, USA) and subjected to enzymatic digestion in accordance with the previous report (Orth and Boehm, 1990) . Seminiferous cord fragments free from interstitial cells were harvested and were treated with 0.05% trypsin 5.3610 74 M EDTA (Life Technologies Inc., MD, USA) for 7 min at 378C. The ®nal single cell suspension in Dulbecco's modi®ed Eagle's medium (DMEM, Life Technologies Inc., MD, USA) containing 2% FBS was plated on gelatin-coated 100-mm plate at 5610 5 cells density and incubated for 6 h at 378C. The adherent cells were washed with serum-free MEM three times to remove gonocytes and then subjected to total RNA puri®cation. At that moment, adherent cells consist of 98%5Sertoli cells.
RNA preparation and Northern blot hybridization
AxCANCre were injected into a right testis of the conditional transgenic mouse. Left testis of the transgenic mouse remained untreated. Twenty-four hours after the injection, total RNAs were prepared from both Cre-injected and -uninjected testis, and other tissues such as brain, lung, liver, and kidney by using Isogen solution (Nippon Gene, Tokyo) according to the manufacturer's protocol. Expression of mRNA for HST-1/FGF-4 gene was examined by Northern blot hybridization under high stringency condition with a 32 Plabeled human Fgf-4 cDNA fragment as a probe. Native mouse Hst-1/Fgf-4 gene expression has not been detected in adult tissues by human FGF-4 cDNA probe because of its low expression level. The same RNA samples were subjected to RT ± PCR analysis of b-actin transcripts.
RT ± PCR analysis
Cellular and tissue total RNA samples were prepared using Isogen solution (Nippon Gene, Tokyo) according to the manufacturer's protocol. An aliquot of total RNA isolated was treated with DNase (DNase I, ampli®cation grade; Life Technologies Inc., MD, USA), and poly(A) + RNAs were puri®ed in Sertoli cell samples. RT ± PCR reaction was performed using QIAGEN OneStep RT ± PCR kit (QIAGEN K.K., Japan) with the following primers: 5'-TTCTTCGTGGCCATGAGCA-3' and 5'-TGACCTTCATG-GTGGGCGACA-3' for human HST-1/FGF-4. After 30 min at 508C for reverse transcription reaction, the reaction was terminated at 948C for 15 min, and PCR was then performed with 35 cycles in a Perkin-Elmer Thermal Cycler using a cycle pro®le of 1 min at 978C, 1 min at 608C and 40 s at 728C. After RT ± PCR, aliquots were run on 3.0% agarose gels, stained with ethidium bromide, and then photographed under UV illumination. This primer set does not recognize native mouse Hst-1/Fgf-4 gene expression under our RT ± PCR conditions. b-actin cDNA was ampli®ed as an internal control using primers 5'-GACATCAAAGAGAAGCTGTGC-3' and 5'-TAGGAGC-CAGAGCAGTAATC-3'.
Labeling index and immunohistochemistry
Animals received an intraperitoneal injection of 5-BrdU (100 mg/kg body weight, Sigma-Aldrich, Japan) 2 h before being sacri®ced. To determine the BrdU labeling index, the testes of each animal were ®xed in Carnoy's ®xative and embedded in paran. Sections were made and processed immunohistochemically using the BrdU staining kit (Roche Diagnostics, GmbH, Germany) according to the recommended method. Using a microscope, the percentage of BrdU-labeled cells was determined by counting at least 200 seminiferous tubules cross-sections per testis.
ADR treatment and assessment of spermatogenesis
Transgenic mice (male, 10 weeks old) were divided into two groups. One group received AxCANCre, and the other group received control AxCAwt. The number of mice in each group was 30. Seven days after the adenovirus injection, adriamycin (ADR), an anticancer drug, was intraperitoneally administered to 10-to 11-week-old C57BL/6J or transgenic male mice at a dose of 2 mg/kg once a week for 3 weeks, and then body weight, testis weight, sperm count, sperm motility and DNA ploidy were observed periodically. The experiment was repeated three times. Sperm were counted by the following method. Spermatozoa were collected by mincing caudal epididymis and incubated in modi®ed Krebs-Ringer bicarbonate solution (Ivanova et al., 1999) with 4 mg/ml of bovine serum albumin (Sigma-Aldrich, Japan) at 378C. The sperm suspension was incubated for 30 min at 378C, and sperm count was determined by an added 1/10 volume of 5 M NaCl. Sperm motility was assessed by light microscopy after incubating for 1 h at 378C as described, and the data were represented as a percentage of motile sperm per more than Increased sperm count by HST-1/FGF-4 H Yamamoto et al 1000 counts. The DNA histograms were analysed according to the described method by using propidium iodide (PI) staining (Hellstrom et al., 1990) . DNA histograms were collected by automated¯ow cytometry. For the examination of testis histology, standard periodic acid Schi and hematoxylin and eosin staining were performed after the ®xation with Bouin solution and counted 200 seminiferous tubules cross-sections per testis (Grell et al., 1980) . The germ cells were recognized and counted by using morphological criteria according to the described methods (Oakberg and Huckins, 1976) . Mice were housed with normal C57BL/6J female mice overnight on a 1 : 1 basis to examine male fertility.
AxHST-1 administration into testis C57BL/6J mice received ADR at a dose of 2 mg/kg once a week for 3 weeks. Four weeks later, mice were divided into two groups and received either an intratesticular injection of AxHST-1, which was previously used for signi®cant expression of HST-1/FGF-4 in vivo (Takahama et al., 1999) , or control AxCAwt at a dose of 1.0610 8 p.f.u./testis. Ten days after the treatment, they were sacri®ced for the examination of cauda epididymal sperm pro®les and the morphology and weight of the testes.
Statistical analysis
The results are represented as means+s.d. Student's t-test was performed for statistical evaluation, with P50.05 considered as signi®cant.
